Baric Transcribed Interview (Redacted) — page 119

DC.Scheduling@LexitasLegal.com MS. SALAZAR: Okay. And how much are shipping costs? DR. BARIC: You know, I haven't shipped anything. I have somebody else I have to do it. We have a person who's trained as a shipper, and they take care of it. MS. SALAZAR: Okay. I want to go back to the DARPA question on PREEMPT. I'll show you this email, and I don't have another copy of it right now. But it is dated March 7, 2019. It's from Vineet Menarchery, and you have a couple of other folks on here from Autonomous Therapeutics. [Exhibit No. 3 shown.] MS. SALAZAR: It says, "Ralph, I've been working on a DARPA proposal with Autonomous Therapeutics on MERS-CoV with a quick turnaround. They're funded for another DARPA project to generate therapeutic interfering particles, and are looking to apply their approach for MERS on this specific supplement call. We have been chatting for a few weeks, and they are interested in both in vitro and in vivo experiments with their MERS-CoV targeted TIPs. I am currently planning to work with them on the in vitro side, but suggest they talk directly to you about the DPPR 288/330 model." DR. BARIC: Okay. MS. SALAZAR: Do you recognize this? DR. BARIC: Within the contest of Vineet, yes. MS. SALAZAR: Did you end up doing work with --